Value of alpha-methylacyl-CoA racemase immunochemistry for predicting neoplastic progression in Barrett's oesophagus

Florine Kastelein, Katharina Biermann, Ewout Steyerberg, Joanne Verheij, Marit Kalisvaart, LHJ (Leendert) Looijenga, Hans Stoop, L Walter, Ernst Kuipers, Manon Spaander, Marco Bruno

Research output: Contribution to journalArticleAcademicpeer-review

27 Citations (Scopus)


AimTo investigate the value of -methylacyl-CoA racemase (AMACR) immunohistochemistry for predicting neoplastic progression in Barrett's oesophagus (BO). Methods and resultsWe conducted a case-control study within a prospective cohort of 720 BO patients. Patients who developed high-grade dysplasia or oesophageal adenocarcinoma were classified as cases, and patients without neoplastic progression as controls. AMACR expression was determined by immunohistochemistry in 12127 biopsies from 635 patients, and was scored independently by two expert pathologists. Relative risks adjusted for age, gender, BO length and oesophagitis (RRa) were calculated in ConclusionsStrong AMACR expression is associated with an increased risk of neoplastic progression in BO. However, AMACR expression appears to be a less powerful predictor for neoplastic progression than low-grade dysplasia.
Original languageUndefined/Unknown
Pages (from-to)630-639
Number of pages10
Issue number5
Publication statusPublished - 2013

Research programs

  • EMC MM-03-24-01
  • EMC MM-04-20-01
  • EMC NIHES-02-65-01

Cite this